Page 109 - NobleCon21

Kalaris Therapeutics, Inc.

SELECTED FINANCIAL ITEMS KLRS
(in millions of USD)
CQ4 '24 CQ1 '25 CQ2 '25 CQ3 '25 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit NA NA NA NA 0.00
Gross Margin NM NM NM NM NM
EBIT (7.13) (10.35) (12.26) (12.74) (42.48)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (22.03) (10.20) (11.35) (11.89) (55.47)
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets 6.16 103.09 92.84 81.18 81.18
Cash & Short Term Investments 1.64 100.97 88.43 42.39 42.39
% of Assets 27% 98% 95% 52% 52%
Current Assets -Total 2.61 102.18 91.65 78.18 78.18
% of Assets 42% 99% 99% 96% 96%
Total Liabilities 56.78 39.22 39.73 39.31 39.31
% of Assets 921% 38% 43% 48% 48%
Current Liabilities - Total 24.70 7.14 7.65 6.07 6.07
% of Assets 401% 7% 8% 7% 7%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity (50.62) 63.87 53.12 41.87 41.87
% of Assets -821% 62% 57% 52% 52%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (7.85) (7.44) (12.54) (11.33) (39.16)
Net Cash Flow - Investing NA NA NA (34.71) (34.71)
Net Cash Flow - Financing 7.58 107.27 0.00 0.00 114.84

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference